Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00867152 · ClinicalTrials.gov registry record · Phase 1

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

A Phase 1 study, sponsored by ViiV Healthcare.

Completed
Registry status
Phase 1
Development phase
17
Enrollment target

NCT00867152: Completed Phase 1 study, sponsored by ViiV Healthcare.

NCT00867152 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00867152, a Phase 1 study, has completed, sponsored by ViiV Healthcare.

COMPLETED
Registry status
Phase 1
Development phase
17 participants
Enrollment target

Study Summary

A Phase I, open label, randomized, three period, one-way, two cohort, adaptive crossover study to evaluate the effect of darunavir/ritonavir plus etravirine and lopinavir/ritonavir plus etravirine on GSK1349572 pharmacokinetics in healthy adult subjects

Interventions

  • DRUG Ritonavir
  • DRUG Etravirine
  • DRUG Darunavir
  • DRUG GSK1349572
  • DRUG Lopinavir/ritonavir

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2009-04
Est. Completion 2009-05
Phase Phase 1
ViiV Healthcare

182 total trials

What the finished NCT00867152 record still lists

NCT00867152 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).

The record links to 0 conditions, and to 5 interventions - of which Ritonavir is the first listed.

NCT00867152 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00867152 about?

NCT00867152 is a clinical study titled "GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir". A Phase I, open label, randomized, three period, one-way, two cohort, adaptive crossover study to evaluate the effect of darunavir/ritonavir plus etravirine and lopinavir/ritonavir plus etravirine on GSK1349572 pharmacokinetics in healthy adult subjects

What is the current status of trial NCT00867152?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2009-04. Estimated completion is 2009-05.

What interventions are being tested in trial NCT00867152?

The interventions under investigation include: Ritonavir (DRUG), Etravirine (DRUG), Darunavir (DRUG), GSK1349572 (DRUG), Lopinavir/ritonavir (DRUG).

Who is sponsoring clinical trial NCT00867152?

This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00867152's enrollment target sits among peer trials

17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00867152, the US trial registry maintained by the National Library of Medicine. NCT00867152 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.